托珠单抗治疗Covid-19肺炎住院患者
EMPACTA研究为2:1随机对照试验,纳入389例未接受机械通气的Covid-19肺炎住院患者,重点入组高风险及少数族裔人群。托珠单抗组(8 mg/kg静脉,1或2剂)28天内机械通气或死亡累积发生率为12.0%,安慰剂组为19.3%(HR 0.56,95%CI 0.33-0.97,P=0.04)。28天全因死亡两组分别为10.4%与8.6%(加权差2.0个百分点,95%CI -5.2至7.8)。严重不良事件托珠单抗组15.2%,安慰剂组19.7%。
要点
- 适用人群为未接受机械通气的Covid-19肺炎住院患者,托珠单抗8 mg/kg静脉给药1或2剂,联合标准治疗。
- 主要终点28天内机械通气或死亡:托珠单抗组12.0% vs 安慰剂组19.3%,HR 0.56(95%CI 0.33-0.97),P=0.04。
- 28天全因死亡托珠单抗组10.4% vs 安慰剂组8.6%,加权差2.0个百分点(95%CI -5.2至7.8),未显示生存获益。
- 临床失败时间事件分析 favoring 托珠单抗(HR 0.55,95%CI 0.33-0.93)。
- 严重不良事件托珠单抗组15.2%(38/250) vs 安慰剂组19.7%(25/127),未见新安全信号。
适用人群与场景
- 住院的Covid-19肺炎患者,未接受机械通气;研究入组重点关注高风险及少数族裔人群(56.0% Hispanic或Latino,14.9% Black,12.7% American Indian或Alaska Native,12.7% non-Hispanic White,3.7%其他或未知种族/族裔)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 标准治疗加用托珠单抗8 mg/kg体重静脉给药,1或2剂;或标准治疗加安慰剂;随机分组比例2:1(托珠单抗:安慰剂)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 随机对照试验,389例患者随机,改良意向治疗人群托珠单抗组249例、安慰剂组128例;主要终点28天内机械通气或死亡累积发生率:托珠单抗组12.0%(95%CI 8.5-16.9) vs 安慰剂组19.3%(95%CI 13.3-27.4),HR 0.56(95%CI 0.33-0.97),P=0.04(log-rank检验)。
- 临床失败时间事件分析:HR 0.55(95%CI 0.33-0.93), favor 托珠单抗。
- 28天全因死亡:托珠单抗组10.4% vs 安慰剂组8.6%,加权差2.0个百分点(95%CI -5.2至7.8)。
- 安全性人群严重不良事件:托珠单抗组38/250(15.2%) vs 安慰剂组25/127(19.7%);未见新安全信号。
证据类型、等级与局限
- 随机对照试验(RCT),2:1随机、安慰剂对照、双盲(原文未明确盲法,但提及安慰剂);由Genentech资助;EMPACTA试验(NCT04372186)。
- 局限:原文未明确提及盲法细节;研究重点入组高风险及少数族裔人群,可能影响外推性;样本量389例。
对床旁实践的改变
- 对于未接受机械通气的Covid-19肺炎住院患者,可考虑托珠单抗8 mg/kg静脉给药1或2剂以降低机械通气或死亡复合终点,但需注意未改善生存。
- 不适用于已接受机械通气的患者(研究排除该人群)。
- 需权衡获益(减少机械通气或死亡复合终点)与无生存获益及严重不良事件风险(托珠单抗组15.2% vs 安慰剂组19.7%)。
指南或共识出处
- N Engl J Med: Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia (EMPACTA, NCT04372186).
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti-interleukin-6 receptor antibody tocilizumab in patients from these populations who are hospitalized with Covid-19 pneumonia are unclear.
METHODS: We randomly assigned (in a 2:1 ratio) patients hospitalized with Covid-19 pneumonia who were not receiving mechanical ventilation to receive standard care plus one or two doses of either tocilizumab (8 mg per kilogram of body weight intravenously) or placebo. Site selection was focused on the inclusion of sites enrolling high-risk and minority populations. The primary outcome was mechanical ventilation or death by day 28.
RESULTS: A total of 389 patients underwent randomization, and the modified intention-to-treat population included 249 patients in the tocilizumab group and 128 patients in the placebo group; 56.0% were Hispanic or Latino, 14.9% were Black, 12.7% were American Indian or Alaska Native, 12.7% were non-Hispanic White, and 3.7% were of other or unknown race or ethnic group. The cumulative percentage of patients who had received mechanical ventilation or who had died by day 28 was 12.0% (95% confidence interval [CI], 8.5 to 16.9) in the tocilizumab group and 19.3% (95% CI, 13.3 to 27.4) in the placebo group (hazard ratio for mechanical ventilation or death, 0.56; 95% CI, 0.33 to 0.97; P = 0.04 by the log-rank test). Clinical failure as assessed in a time-to-event analysis favored tocilizumab over placebo (hazard ratio, 0.55; 95% CI, 0.33 to 0.93). Death from any cause by day 28 occurred in 10.4% of the patients in the tocilizumab group and 8.6% of those in the placebo group (weighted difference, 2.0 percentage points; 95% CI, - 5.2 to 7.8). In the safety population, serious adverse events occurred in 38 of 250 patients (15.2%) in the tocilizumab group and 25 of 127 patients (19.7%) in the placebo group.
CONCLUSIONS: In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival. No new safety signals were identified. (Funded by Genentech; EMPACTA ClinicalTrials.gov number, NCT04372186.).
参考来源
- Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2020. PMID: 33332779. doi:10.1056/NEJMoa2030340
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。